Vancouver, BC, November 29, 2019--Phoenix Molecular Designs(PhoenixMD), a clinical stage biotechnology company developing precise cancer therapeutics targeting essential kinases, announced that it has dosed the first patient in its Phase 1/1b study of PMD-026, the company's lead product candidate.
|